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Abstract
Using haloperidol as a scaffold, new agents were designed to investigate the structural
contributions of various groups to binding at CNS receptors associated with atypical antipsychotic
pharmacology. It is clear that each pharmacophoric group, the butyrophenone, the piperidine and
the 4-chlorophenyl moieties contributes to changes in binding to the receptors of interest. This
strategy has resulted in the identification of several new agents, compounds 16, 18, 19, 23, 24 and
25, with binding profiles which satisfy our stated criteria for agents to act as potential atypical
antipsychotics. This research demonstrates that haloperidol can serve as a useful lead in the
identification and design of new agents that target multiple receptors associated with antipsychotic
pharmacology.
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1. Introduction
Until recently, haloperidol (1) has been a drug of choice in the treatment of schizophrenia
and has represented the typical antipsychotic drugs as a mainstay of treatment from the
1960s until this decade.1 While its therapeutic effectiveness has been attributed to potent
dopamine (DA) D2 receptor binding affinity (D2 Ki = 0.89 nM), haloperidol also binds with
low to high affinity at several other central nervous system (CNS) receptors, including other
DA subtypes, serotonin (5-HT) receptors and alpha (α) adrenoceptors (Tables 1 and 4).
Thus, haloperidol can serve as a scaffold for the design of new agents that target multiple
receptors associated with antipsychotic pharmacology.
The dwindling interest in haloperidol and other typical antipsychotics is partially related to
the induction of severe short- and long-term debilitating movement disorders including
Parkinsonism-like symptoms, sometimes referred to as extrapyramidal syndrome (EPS) and
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tardive dyskinesia (TD).2,3 Several theories have been proposed to explain haloperidol’s
long-term side effects including metabolic transformation of the piperidine moiety to
quaternary pyridinium (BCPP+) species which have similar but weaker potential as 1-
methyl -4- phenyl pyridinium (MPP+) to destroy D2 receptors in the substantia nigra of the
brain.4,5 More recently, Kim and others have shown that N-dealkylation of the
butyrophenone moiety to produce 3-(4-fluorobenzoyl) propionic acid (FBPA) (Figure 1)
may also contribute to haloperidol’s EPS problems.6 These theories have inspired us to
begin a search for drugs that could not be transformed in vivo to produce the harmful
metabolites.7 Our laboratory has been interested in the potential of haloperidol as a lead to
obtain novel entities without EPS but which display multi-receptor binding profiles similar
to those of atypical antipsychotic agents. Towards this end, we have designed and
synthesized new agents based on the haloperidol pharmacophore which could not be
transformed into the toxic quaternary metabolites, but which possess atypical antipsychotic
binding profiles.7–10 In furtherance of this interest, the current study explores the effect of
the replacement of both butyrophenone and piperidine moieties in haloperidol with
bioisosteres that could not be bio-transformed into toxic metabolites, i.e., BCPP+ and FBPA
respectively.
In previous studies, we have proposed a set of binding criteria that would lead to new agents
without the known side effects observed with the atypical antipsychotic agents in use.9
These include: compounds should bind with moderate affinity at the D2 receptor (30 nM <
Ki < 150 nM), as avid affinity to this receptor may lead to induction of acute EPS; and a
weak or no binding affinity to 5HT2C and histamine H1 receptors, as both receptors are
reported to be associated with weight gain and subsequently type II diabetes, often observed
with some of the atypical antipsychotics.
2. Chemistry
Alkylating agent, 1-fluoro-4-(4-iodobutyl)benzene (2) was prepared using a literature
procedure with modification11 by coupling 4-fluorophenyl magnesium bromide with 1,4-
dibromobutane in the presence of Li2CuO4, and followed by halide exchange in acetone
under reflux (Scheme 1). Coupling of 2 with selected amines in DME using K2CO3 as base
provided ligands 5, 12, 20, 23 (Tables 1–3). 3-(4-fluorophenoxy)propan-1-ol, 3a was
obtained by refluxing 4-fluorophenol, 3-chloropropanol, K2CO3, and KI in iPrOH.
Mesylation was carried out at room temperature employing Et3N as a base to afford 3-(4-
fluorophenoxy)propyl methane sulfonate, 4a (Scheme 3). Methane sulfonates, 4b and 4c
were similarly synthesized. Alkylation of selected amines in the presence of K2CO3 and KI
in DME, with methane sulfonates (4a, 4b and 4c) resulted in the formation of compounds 6–
9, 13–18, 21–23 and 24–26 (Tables 1–3). The syntheses of these compounds are shown in
Scheme 4. Sulfoxide 10 was obtained by oxidation of 9 with m-CPBA in MeOH as shown in
scheme 5.
3. Results and discussion
The first strategy was to conduct preliminary SAR studies on haloperidol to observe how
changes in the various segments of the structure affect binding at DA and 5HT receptor
subtypes of interest. The structure was delineated in 3 segments, the butyrophenone moiety,
the piperidine and the 4-chlorophenyl moiety as depicted below.
Peprah et al. Page 2













The butyrophenone moiety was the focus of the first modifications and these modifications
are referenced to haloperidol. Reduction of the carbonyl to a methylene group 5 (D2 Ki =
24.0 nM) resulted in a 27-fold decrease in binding to the D2 receptor compared to
haloperidol (Table 1). Replacement of the carbonyl group with sulfur 6 (D2 Ki = 8.8 nM)
and oxygen 7 (D2 Ki = 5.3 nM) resulted in more moderate decreases in affinity at the D2
receptor. Overall, with the piperidinol in place, the carbonyl appears to be an important
group for binding to D2 receptors but is not a necessary group since it can be replaced by a
methylene group, sulfur, or oxygen to display potent binding at the D2 receptor. The trend in
binding at the D2 receptor is an increase from the methylene group to sulfur and then to
oxygen. Binding to the D3 receptor for the three compounds shows little or no observable
pattern although the sulfur analog displayed the highest potency among them. At the D4
receptor, the sulfur analog displayed over 24-fold decrease in binding while the oxygen
analog displayed over 4-fold increase in binding compared to the methylene analog. A
significant observation relates to the binding of two of the compounds to 5HT receptor
subtypes. Compound 7, the oxygen analog, displayed a 49-fold increase in binding (Ki =
74.0 nM) at the 5HT1A receptor while compound 6 bound with a moderate increase in
affinity (Ki = 317.0 nM) compared to haloperidol. At the 5HT2A receptor, the methylene
substituent had a moderate binding affinity while the sulfur (Ki = 72.0 nM) and oxygen (Ki
= 93.0 nM) analogs displayed increased binding over haloperidol.
The next SAR focus was on the piperidine moiety. Removal of the alcohol function from
compounds 6 and 7 to form 8 and 9 respectively resulted in significant decreases in binding
to the D2 receptor as observed in previous reports.7 However, there was an increase in
binding for the sulfur analog 8 (Ki = 39.0 nM) and a more moderate decrease in binding at
the D4 receptor for the oxygen analog 9 (Ki = 9.5 nM). At both the 5HT1A and 5HT2A
receptors, the absence of the alcohol group did not result in much change in binding. It is
interesting to note that oxidizing the sulfur analog 8 to form the sulfoxide 10 which appears
to mimic the carbonyl moiety structurally, resulted in diminished binding at all the receptors
examined except at the 5HT1A receptor and thus suggests that the sulfoxide may not serve as
a bioisostere of the carbonyl group. The next evaluation, replacement of the piperidine with
a piperazine resulted in analogs 11–18. Compound 11, the piperazine analog of haloperidol,
produced a substantial decrease in affinity to the D2 receptor from 0.89 nM to 253.5 nM.
Binding affinity decreased or changed minimally at essentially all the other receptors
evaluated. Reduction of the carbonyl to a methylene group to form compound 12 did not
modify binding significantly at these receptors. Likewise, replacement of the carbonyl with
sulfur 13 and oxygen 15 did not result in significant changes in binding at dopamine and
serotonin receptors of interest. In the eastern hemisphere, replacement of the 4-chloro atom
on the phenyl ring with the bigger and more powerful electron withdrawing CF3 group 14
led to a dramatic decrease in binding affinity at all the receptor subtypes investigated. This
may suggest there is a steric obstruction to binding at these receptors. The contributions of
the two halogens in the western and eastern hemispheres were also evaluated using
compound 15 as the template. Compound 16, with the chloro atom removed, binds at the D2
receptor with 37 nM affinity, this being an over 10-fold increase in binding. Removal of the
Peprah et al. Page 3













4'-fluoro atom while retaining the 4-chloro atom 17 did not result in an increase in binding
but instead led to significant decreases except for the 5HT1A receptor where binding
increased by a factor of 3 (5HT1A, Ki = 19.8 nM). When both halides were removed to
obtain compound 18, binding improved at all receptors of interest compared to 17 but was
mixed compared to compound 16.
We also investigated replacements of the 4-chlorophenyl ring with heteroaromatic rings
associated with increased binding at 5HT receptors. Replacement of the 4-chlorophenyl
group in compound 11 with the 2-pyrimidinyl group to obtain compound 19, led to
improvement in binding affinity at all the receptors investigated. Reduction of the carbonyl
group to a methylene group 20 did not improve binding at the D2-like and the 5HT2A
receptors but did improve binding affinity at the 5HT1A receptor (19 (Ki = 30.5 nM); 20 (Ki
= 8.6 nM)). Replacement of the carbonyl group with sulfur 21 or oxygen 22 did not result in
any significant modifications of binding affinity at the receptors investigated. Replacing the
2-pyrimidinyl group in compounds 20, 21 and 22 with a 2-pyridinyl moiety to form 23, 24
and 25 respectively were also evaluated. Compound 23 binds with increased affinity at the
D2-like receptors and also shows either an increased potency or no changes at the serotonin
receptor subtypes investigated. In fact, compound 23 has the highest binding affinity (Ki =
1.1 nM) at the 5HT1A receptor in this investigation. Compounds 24 and 25, the sulfur and
oxygen analogs also showed significant D4 potency and selectivity and high affinity binding
to 5HT1A and 5HT2A.
A review of how the current compounds under investigation have satisfied our criteria9 for
obtaining new antipsychotic agents with moderate D2 binding and high affinity binding (Ki
< 50 nM) to 5HT1A and 5HT2A receptors shows several compounds including 16, 18, 19,
23, 24, and 25 meet the stated criteria and were therefore slated for further evaluation.
These compounds were thus screened for their binding affinities at 5HT7, α2c and M1 to
assess their capacity to improve cognitive properties. They showed only moderate binding
affinity at the 5HT7 receptor, and similar affinity at the α2C receptor. The 5-HT7 receptor
abounds in the hippocampus, which is involved in learning and memory.12 Studies have
shown that 5-HT7 receptor antagonists and 5-HT7 receptor gene knockout have the potential
to impair some cognitive functions in mice.13 The adrenergic α2c receptor has also been
implicated as potentially relevant to cognitive function.14 Evaluation at M1 receptors
showed the compounds to have little or no affinity at the muscarinic M1 receptor (Table 4).
The blockade of this cholinergic receptor has been associated with cognitive deficits, which
may be particularly severe in susceptible individuals such as the elderly.15 The propensity of
the compounds to induce metabolic side-effects such as weight gain was investigated by
evaluating their binding affinities at H1 and 5HT2C receptors. The results are recorded in
Table 4. All the 6 compounds evaluated bind with only moderate affinity at the H1 receptor
and have little or no binding to the 5HT2C receptor. Histamine H1 receptor blockade has
been implicated in weight gain associated with atypical antipsychotic therapy16,17 and so has
the 5HT2C receptor.18,19 This suggests that these compounds would have attenuated
capacity to induce weight gain.
Overall, the SAR of haloperidol indicates the butyrophenone, the piperidine and the 4-
chlorophenyl moieties each play a role in its multi-receptor binding profile. Six compounds
(16, 18, 19, 23, 24 and 25) have been identified as meeting the general criteria we have
proposed as sufficient to be considered for further evaluation. Based on further screening
results, there is sufficient data to engender evaluation of these compounds in vivo in order to
understand the pharmacology imposed on them as a result of the binding profiles observed.
These in vivo evaluations are currently underway.
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Melting points were determined on a Gallenkamp (UK) apparatus and are uncorrected.
NMR spectra were obtained on a Varian 300 MHz Mercury Spectrometer. Elemental
analyses were carried out by Atlantic Microlab, Inc., Norcross, GA, and are within 0.4% of
theory unless otherwise noted. Flash chromatography was performed with Davisil grade 634
silica gel. N,N-Dimethylformamide was distilled from CaSO4 and stored over 4Å molecular
sieves. 4-Chloro-4´-fluorobutyrophenone was obtained from Sigma-Aldrich, but was
purified by distillation under reduced pressure to a colorless liquid prior to use. Other
starting materials were used without further purification.
4.1. 1-Fluoro-4-(4-iodobutyl)benzene (2)
This iodide was prepared following a literature procedure.20 The bromide was first obtained,
followed by halide exchange to obtain the iodide. Yield 82.1% 1H NMR (CDCl3): δ 7.13
(2H, m), 6.98 (2H, m), 3.20 (2H, t, J = 6.6 Hz), 2.62 (2H, t, J = 7.8 Hz), 1.84 (2H, m), 1.73
(3H, m).
4.1.1. General procedure for the synthesis of methanesulfonates (4a, 4b, 4c)—
A mixture of 4-fluorophenol (1.1 g, 10 mmol), 3-chloropropanol (1.4 g, 15 mmol), KI (50
mg), K2CO3 (2.8 g, 20 mmol) in iPrOH was refluxed under N2 for 1 h. The mixture was
diluted with EtOAc (200 mL), and washed with water (50 mL), brine (50 mL). The organic
layer was dried with Na2SO4, and filtered. The filtrate was concentrated in vacuo, and
followed by distillation in vacuo to give the desired product 3-(4-fluorophenoxy)propan-1-ol
(3a). To a solution of 3a (1.3 g, 7.6 mmol), Et3N (3 mL) in CH2Cl2 (10 mL) was added at
room temperature MsCl (0.8 mL, 10.3 mmol). The mixture was stirred at room temperature
for 12 h, followed by direct purification through column chromatography on silica gel, to
provide 3-(4-fluorophenoxy)propyl methanesulfonate (4a).
4.1.2. 3-(4-Fluorophenoxy)propan-1-ol (3a)—Yield 90%. 1H NMR (CDCl3): δ 6.96
(2H, t, J = 8.4 Hz), 6,84 (2H, dd, J = 4.5, 9.0 Hz), 4.09 (2H, t, J = 6.0 Hz), 3.85 (2H, m),
2.03 (2H, m).
4.1.3. 3-(4-Fluorophenylthio)propan-1-ol (3b)—Yield 72%. 1H NMR (CDCl3): δ 7.35
(2H, dd, J = 5.4, 8.4 Hz), 6.99 (2H, t, J = 8.4 Hz), 3.76 (2H, t, J = 6.0 Hz), 2.98 (2H, t, J =
7.2 Hz), 1.85 (2H, m).
4.1.4. 3-Phenoxy-propan-1-ol (3c)—Yield 75%. 1H NMR (CDCl3): δ 7.29 (2H, m),
6.93 (3H, m), 4.13 (2H, t, J = 6.0 Hz), 3.88 (2H, m), 2.06 (2H, m), 1.90 (1H, brs).
4.1.5. 3-(4-Fluorophenoxy)propyl methanesulfonate (4a)—Yield 95%. 1H NMR
(CDCl3): δ 6.97 (2H, t, J = 8.1 Hz), 6.83 (2H, dd, J = 4.5, 9.0 Hz), 4.44 (2H, t, J = 6.0 Hz),
4.05 (2H, t, J = 6.0 Hz), 2.21 (2H, m).
4.1.6. 3-((4-Fluorophenyl)thio)propyl methanesulfonate (4b)—Yield 94%. 1H
NMR (CDCl3): δ 7.37 (2H, dd, J = 9.0, 4.8 Hz), 7.00 (2H, t, J = 9.0 Hz), 4.30 (2H, t, J = 8.0
Hz), 3.00 (3H, s), 2.78 (2H, t, J = 7.2 Hz), 2.02 (2H, m).
4.1.7. 3-Phenoxypropyl methanesulfonate (4c)—yield 92%. 1H NMR (CDCl3): δ
7.30 (2H, m), 6.97 (1H, m), 6.90 (2H, m), 4.43 (2H, t, J = 6.3 Hz), 4.08 (2H, t, J = 6.0 Hz),
2.97 (3H, s), 2.21 (2H, m).
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4.1.8. General procedure for coupling iodides with amines—A mixture of 1-
fluoro-4-(4-iodobutyl)benzene (2) (1.58 g, 5.7 mmol), 4-(4’-chlorophenyl) piperidin-4-ol
(1.0 g, 4.7 mmol), and K2CO3 (1.96 g, 17 mmol) in DME (25 mL) was refluxed under N2
for 12 h with stirring. The mixture was diluted with EtOAc (500 mL) and washed with water
(300 mL). The organic phase was collected, dried with sodium sulfate, and filtered. The
filtrate was concentrated by evaporation under reduced pressure, followed by purification
using column chromatography with hexane: EtOAc (1: 4) as eluent to afford 4-(4'-
chlorophenyl)-1-(4'-(4-fluorophenyl)butyl)piperidin-4-ol (5) (0.83 g) as an off-white solid
after crystallization in EtOAc/Et2O; yield 48.5%, mp 140–141 °C. 1H NMR (CDCl3): δ 7.26
(2H, m), 7.15 (2H, d, J = 4.5 Hz), 6.95 (2H, m), 6.87 (2H, m), 3.98 (2H, t, J = 6.6 Hz), 3.06
(2H, d, J = 5.7 Hz), 2.54 (2H, t, J = 6.9 Hz), 1.98 (4H, m), 1.80 (4H, m). Calcd for
C21H25ClFNO•0.2 H2O: C 69.01, H 6.89, N 3.83; Found: C 68.82, H 6.86, N 3.82.
4.1.9. 1-(4-Chlorophenyl)-4-(4-(4-fluorophenyl)butyl)piperazine (12)—Using 2
and 1-(4-chlorophenyl) piperazine, produced compound 12: yield 52.2%, mp 89–90 °C. 1H
NMR (CDCl3): δ 7.19 (2H, m), 7.13 (2H, m), 6.95 (2H, m), 6.84 (2H, m), 3.14 (4H, m),
2.56 (6H, m), 2.39 (2H, t, J = 7.5 Hz), 1.59 (4H, m). Calcd for C20H24ClFN2: C 69.97, H
6.97, N 8.08; Found: C 69.29, H 7.03, N 7.91.
4.1.10. 2-(4-(4-(4-Fluorophenyl)butyl)piperazin-1-yl)pyrimidine (20)—Using 2 and
2-(piperazin-1-yl)pyrimidine, produced compound 20; yield 51.7%, mp 54–55 °C. 1H NMR
(CDCl3): δ 8.31 (2H, m), 7.12 (2H, m), 6.95 (2H, m), 6.47 (1H, m), 3.82 (4H, m), 2.61 (2H,
t, J = 6.9 Hz), 2.48 (4H, m), 2.38 (2H, m), 1.62 (4H, m). Calcd for C18H23FN4: C 68.76, H
7.37, N 17.82; Found: C 68.47, H 7.45, N 17.64.
4.1.11. 1-(4-(4-Fluorophenyl)butyl)-4-(pyridin-2-yl)piperazine (23)—Using 2 and
1-(pyridin-2-yl)piperazine, produced compound 23; yield 44%, mp 58–59 °C. 1H NMR
(CDCl3): δ 8.19 (1H, m), 7.47 (1H, m), 7.13 (2H, m), 6.96 (2H, m), 6.62 (2H, m), 3.54 (4H,
t, J = 4.8 Hz), 2.61 (2H, t, J = 7.2 Hz), 2.53 (4H, t, J = 5.1 Hz), 2.39 (2H, t, J = 7.8 Hz), 1.60
(2H, m). Calcd for C19H24FN3•0.1H2O: C 72.40, H 7.67, N 13.33; Found: C 72.39, H 7.81,
N 13.14.
4.1.12. General procedure for the coupling reaction of methanesulfonates with
amines—A mixture of 3-(4-fluorophenylthio)propyl methanesulfonate (4b) (1.0 g, 3.79
mmol), 4-(4-chloro-phenyl)-piperidin-4-ol (0.8 g, 3.79 mmol), KI (120 mg), K2CO3 (1.2 g,
8.7 mmol) in DME (10 mL) was heated to reflux under N2 for 12 h. The cooled mixture was
then diluted with EtOAc (400 mL) and washed with H2O (200 mL). The organic layers were
pooled, dried with Na2SO4, and filtered. The filtrate was concentrated in vacuo, then
followed by purification through column chromatography on silica gel, to afford 4-(4-
chlorophenyl)-1-(3-((4-fluorophenyl)thio)propyl)piperidin-4-ol (6); yield 74%, mp 121–122
°C. 1H NMR (CDCl3): δ 7.43 (2H, d, J = 8.4 Hz), 7.35 (2H, dd, J = 4.8, 8.7 Hz), 7.31 (2H,
d, J = 8.4 Hz), 6.99 (2H, t, J = 8.4 Hz), 2.92 (2H, t, J = 7.5 Hz), 2.75 (2H, m), 2.51 (2H, t, J
= 7.8 Hz), 2.41 (2H, m), 2.08 (2H, m), 1.82 (2H, m), 1.70 (2H, m). Calcd for
C20H23ClFNOS: C 63.23, H 6.10, N 3.69; Found: C 63.08, H 6.12, N 3.71.
4.1.13. 4-(4-Chloro-phenyl)-1-[3-(4-fluoro-phenoxy)-propyl]-piperidin-4-ol (7)—
Using 3-(4-fluorophenoxy)propyl methanesulfonate (4a) and 4-(4-chlorophenyl)
piperidin-4-ol, produced compound 7; yield 43.8%, mp 140.0–141.4 °C. 1H NMR (CDCl3):
δ 7.45 (2H, d, J = 9.0 Hz), 7.32 (2H, d, J = 9.0 Hz), 6.96 (2H, t, J = 9.0 Hz), 6.84 (2H, dd, J
= 4.5, 9.0 Hz), 4.00 (2H, t, J = 6.0 Hz), 2.85 (2H, m), 2.61 (2H, t, J = 7.5 Hz), 2.49 (2H, t, J
= 9.0 Hz), 2.13 (2H, m), 2.10 (2H, m), 1.74 (2H, m). Calcd for C20H23ClFNO2: C 66.02, H
6.37, N 3.85; Found: C 66.01, H 6.34, N 3.86
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hydrochloride (8)—Using 4b and 4-(4-chlorophenyl)-piperidine produced the free base of
9 which was converted into the HCl salt; yield 82%, mp 172–173 °C. 1H NMR (DMSO-d6):
δ 10.37 (1H, brs), 7.45 (2H, dd, J = 5.1, 8.7 Hz), 7.38 (2H, d, J = 9.0 Hz), 7.22 (2H, t, J = 8.7
Hz), 7.18 (2H, d, J = 9.0 Hz), 3.49 (2H, m), 3.13 (2H, m), 3.20 (4H, m), 2.80 (1H, m), 1.96
(4H, m). Calcd for C20H24Cl2FNS: C 60.00, H 6.04, N 3.50; Found: C 60.32, H 5.99, N
3.54.
4.1.15. 4-(4-Chlorophenyl)-1-(3-(4-fluorophenoxy)propyl)piperidine (9)—Using
4a and 4-(4-chlorophenyl) piperidine, produced compound 8; yield 35.1%, mp 63–65 °C. 1H
NMR (CDCl3): δ 7.26 (2H, d, J = 8.4 Hz), 7.15 (2H, d, J = 8.4 Hz), 6.96 (2H, t, J = 9.0 Hz),
6.84 (2H, dd, J = 9.0, 4.5 Hz), 3.99 (2H, t, J = 6.6 Hz), 3.06 (2H, m), 2.54 (2H, t, J = 6.9
Hz); 2.06 (2H, m), 1.98 (2H, m), 1.77 (4H, m). Calcd for C20H23ClFNO: C 69.09, H 6.66, N
4.03; Found: C 69.49, H 6.80, N 4.04.
4.1.16. 1-(4-Chlorophenyl)-4-(3-((4-fluorophenyl)thio)propyl)piperazine (13)—
Using 4b and 1-(4-chlorophenyl) piperazine dihydrochloride, produced 13; yield 70.3%, mp
85–86 °C. 1H NMR (CDCl3): δ 7.36 (2H, dd, J = 5.1, 8.7 Hz), 7.21 (2H, d, J = 8.7 Hz), 7.01
(2H, t, J = 8.7 Hz), 6.82 (2H, d, J = 8.7 Hz), 3.36 (4H, brs), 2.96 (4H, m), 2.90 (4H, m), 2.03
(2H, m). Calcd for C19H22ClFN2S: C 62.54, H 6.08, N 7.68; Found: C 62.21, H 5.96, N 7.61
4.1.17. 1-(3-((4-Fluorophenyl)thio)propyl)-4-(4-
(trifluoromethyl)phenyl)piperazine HCl (14)—Using 4b and 1-(4-
trifluoromethyl)phenyl)piperazine produced the free base of 14 which was converted to the
HCl salt immediately, 14; yield 78%, mp 213–214 °C. 1H NMR (DMSO-d6): δ 10.44 (1H,
brs), 7.55 (2H, d, J = 9.0 Hz), 7.45 (2H, dd, J = 5.1, 8.7 Hz), 7.20 (2H, t, J = 8.7 Hz), 7.11
(2H, d, J = 9.0 Hz), 3.97 (2H, d, J = 12 Hz), 3.53 (2H, d, J = 12 Hz), 3.21 (4H, m), 3.10 (2H,
m), 3.00 (2H, m), 1.96 (2H, m). Calcd for C20H23ClF4N2S: C 55.23, H 5.33, N 6.44; Found:
C 55.04, H 5.29, N 6.44.
4.1.18. 1-(4-Chlorophenyl)-4-(3-(4-fluorophenoxy)propyl)piperazine (15)—Using
4a and 1-(4-chlorophenyl) piperazine dihydrochloride, produced 15; yield 75.9%, mp 97–98
°C. 1H NMR (CDCl3): δ 7.20 (2H, d, J = 6.0 Hz), 6.96 (2H, t, J = 8.4 Hz), 6.83 (4H, m),
4.00 (2H, t, J = 6.3 Hz), 3.17 (2H, t, J = 5.1 Hz), 2.60 (6H, m), 2.00 (2H, m). Calcd for
C19H22ClFN2O: C 65.42, H 6.36, N 8.03; Found: C 65.22, H 6.40, N 8.01.
4.1.19. 1-(3-(4-Fluorophenoxy)propyl)-4-phenylpiperazine (16)—Using 4a and 1-
phenylpiperazine, produced 16; yield 48.9%, mp 63.1–64.9 °C. 1H NMR (CDCl3): δ 7.26
(m, 2H), 6.95 (m, 4H), 6.84 (3H, m), 4.0 (2H, t, J = 6.3 Hz), 3.22 (4H, m), 2.61 (6H, m),
2.00 (2H, m). Calcd for C19H23FN2O: C 72.58, H 7.37, N 8.91; Found: C 72.59, H 7.37, N
8.73.
4.1.20. 1-(4-Chlorophenyl)-4-(3-phenoxypropyl)piperazine HCl (17)—Using 3-
phenoxypropyl methanesulfonate 4c and 1-(4-chlorophenyl)piperazine produced 17 which
was converted into the HCl salt, followed by re-crystallization from MeOH using EtOAc;
yield of 39%, mp 208–209 °C. 1H NMR (DMSO-d6): δ 11.07 (1H, brs), 7.28 (4H, m), 7.02
(2H, d, J = 9.0 Hz), 6.92 (3H, m), 4.04 (2H, t, J = 6.0 Hz), 3.79 (2H, m), 3.58 (2H, m), 3.27
(2H, m), 3.14 (4H, m), 2.21 (2H, m). Calcd for C19H24Cl2N2O: C 62.13, H 6.59, N 7.63;
Found: C 62.29, H 6.67, N 7.60.
4.1.21. 1-(3-Phenoxypropyl)-4-phenylpiperazine (18)—Using 4c and 1-
phenylpiperazine produced 18 which was converted into the HCl salt followed by re-
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crystallization from MeOH/EtOAc; yield 48%, mp 195–196 °C. 1H NMR (DMSO-d6):
11.07 (1H, brs), 7.26 (4H, m), 6.96 (5H, m), 6.84 (1H, m), 4.05 (2H, t, J = 6.0 Hz), 3.80 (2H,
m), 3.59 (2H, m), 3.28 (2H, m), 3.13 (4H, m), 2.22 (2H, m). Calcd for C19H25ClN2O: C
68.56, H 7.57, N 8.42; Found: C 68.30, H 7.56, N 8.26.
4.1.22. 2-(4-(3-((4-Fluorophenyl)thio)propyl)piperazin-1-yl)pyrimidine (21)—
Using 4b and 2-(piperazin-1-yl)pyrimidine, produced 21; yield 87%. The free base was
converted to the HCl salt; mp 150–151 °C. 1H NMR (DMSO-d6): δ 8.42 (2H, d, J = 4.8 Hz),
7.44 (2H, dd, J = 5.4, 9.0 Hz), 7.19 (2H, t, J = 9.0 Hz), 6.75 (1H, d, J = 4.8 Hz), 4.66 (2H, d,
J = 12 Hz), 3.50 (2H, d, J = 12 Hz), 3.31 (2H, m), 3.18 (2H, m), 3.00 (4H, m), 1.95 (2H, m).
Calcd for C17H22ClFN4S: C, 55.35; H, 6.01; N, 15.19; Found: C 55.35; H 5.86; N 15.19.
4.1.23. 2-(4-(3-(4-Fluorophenoxy)propyl)piperazin-1-yl)pyrimidine (22)—Using
4a and 2-(piperazin-1-yl)pyrimidine hydrochloride, produced 22; yield 54.8%, mp 82–83
°C. 1H NMR (CDCl3): δ 8.34 (2H, d, J = 4.5 Hz), 6.96 (2H, t, J = 8.4 Hz), 6.84 (2H, dd, J =
4.5, 9.0 Hz), 6.47 (1H, t, J = 4.5 Hz), 4.01 (2H, t, J = 6.0 Hz); 3.83 (4H, t, J = 5.4 Hz), 2.55
(6H, m); 2.00 (2H, m). Calcd for C17H21FN4O•0.2H2O: C 63.81, H 6.62, N 17.51; Found: C
64.03, H 6.65, N 17.63.
4.1.24. 1-(3-((4-Fluorophenyl)thio)propyl)-4-(pyridin-2-yl)piperazine (24)—Using
4b and 1-(pyridin-2-yl)piperazine produced 24; yield 48.1%, mp 81–82 °C. 1H NMR
(CDCl3): δ 8.18 (1H, m), 7.46 (1H, m), 7.36 (2H, m), 7.00 (2H, m), 6.62 (2H, m), 3.523
(4H, t, J = 5.4 Hz), 2.94 (2H, t, J = 7.2 Hz), 2.51 (6H, m), 1.82 (2H, m). Calcd for
C18H22FN3S: C 65.23, H 6.69, N 12.68; Found: C 64.97, H 6.58, N 12.53.
4.1.25. 1-(3-(4-Fluorophenoxy)propyl)-4-(pyridin-2-yl)piperazine (25)—Using 4a
and 1-(pyridin-2-yl)piperazine, produced 25; yield 51.2%, mp 73–74 °C. 1H NMR (CDCl3):
δ 8.20 (1H, m), 7.47 (1H, m); 6.95 (2H, m), 6.85 (2H, m), 6.63 (2H, m), 4.000 (2H, t, J = 6.3
Hz), 3.55 (4H, t, J = 4.8 Hz), 2.58 (6H, m), 2.00 (2H, m). Calcd for C18H22FN3O: C 68.55,
H 7.03, N 13.32; Found: C 68.44, H 7.18, N 13.14
4.1.26. 1-(4-Chlorophenyl)-4-(3-((4-fluorophenyl)thio)propyl)-1,4-diazepane (26)
—Using 4b and 1-(4-chlorophenyl)-1,4-diazepane produced 26 which was converted to the
HCl salt and recrystallized from MeOH-Et2O; yield 69%, mp 172–173 °C. 1H NMR
(DMSO-d6): δ 11.2 (1H, s), 7.63 (1H, s), 7.42 (2H, dd, J = 5.4, 9.0 Hz), 7.17 (4H, m), 6.75
(2H, d, J = 9.0Hz), 3.75 (2H, m), 3.41 (4H, m), 3.16 (2H, m), 3.08 (2H, m), 2.99 (2H, t, J =
7.2 Hz), 2.38 (2H, m), 2.10 (2H, m), 1.98 (2H, m). Calcd for C20H26Cl3FN2S: C 53.16, H
5.80, N 6.20; Found: C 53.39, H 5.98, N 6.22.
4.1.27. 4-(4-Chlorophenyl)-1-(3-((4-fluorophenyl)sulfinyl)propyl)piperidine HCl
(10)—To a solution of 1-(3-(4-fluorophenylthio)propyl)-4-(4-chlorophenyl)piperidine (9)
(200 mg, 0.549 mmol) in MeOH was added with stirring m-CPBA (200 mg) at room
temperature. After stirring for 4 h at room temperature, the mixture was diluted with EtOAc
(200 mL) and washed with sat. NaHCO3 (30 mL) and brine (20 mL). The organic layer was
dried over Na2SO4, and filtered. The filtrate was concentrated in vacuo and the residue
subjected to column chromatography on silica gel to afford 4-(4-chlorophenyl)-1-(3-((4-
fluorophenyl)sulfinyl)propyl)piperidine. The product was converted to the HCl salt
immediately and then recrystallized from MeOH-Et2O to yield (178 mg, 78%), mp 196–197
°C. 1H NMR (DMSO-d6): δ 7.75 (2H, dd, J = 5.4, 9.0 Hz), 7.46 (2H, t, J = 9.0 Hz), 7.39
(2H, d, J = 8.4 Hz), 7.24 (2H, d, J = 8.4 Hz), 3.50 (2H, m), 3.13 (2H, m), 3.00 (2H, m), 2.85
(2H, m), 2.06 (1H, m), 1.94 (6H, m). Calcd for C20H24Cl2FNOS: C 57.69, H 5.81, N 3.36;
Found: C 57.54, H 5.84, N 3.40.
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4.2.1. Receptor binding studies
Binding affinities reported in Tables 1–4 were conducted by the National Institute of Mental
Health Psychoactive Drug Screening Program (NIMH-PDSP). Details of the methods and
radioligands used for the binding assays were previously reported.21
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Metabolic Transformation of Haloperidol
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aReagents and conditions: (a) Li2CuO4, THF, N2, −10 °C, 2 h; (b) KI, acetone, 60 °C, 24 h.
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aReagents and conditions: a) KI, K2CO3, iPrOH, 80 °C,12 h; b) MsCl, Et3N, CH2Cl2, 5 °C-
rt.
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aReagents and conditions: a) KI, K2CO3, DME, 90 °C 12 h.
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aReagents and condition: a) m-CPBA, MeOH, rt, 4 h.
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